SEC Form 4 · accession 0001192482-15-000370

Zynerba Pharmaceuticals, Inc. · ZYNE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chairman & Chief Exec. Officer · Director

Period of report

Aug 10, 2015

Accepted (ET)

Aug 10, 2015 · 3:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001621443

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3	Aug 10, 2015	C	26,595	—	A	26,595	I	See footnote
Common Stock^F1,F3	Aug 10, 2015	C	13,297	—	A	13,297	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series 1 Convertible Preferred Stock^F3,F1,F2	—	Aug 10, 2015	C	50,000	D	—	—	Common Stock	26,595	0	I
Series 1 Convertible Preferred Stock^F3,F1,F2	—	Aug 10, 2015	C	25,000	D	—	—	Common Stock	13,297	0	I

F1The Series 1 Convertible Preferred Stock converted into Zynerba Pharmaceuticals, Inc. common stock on a 1.88-for-1 basis.
F2The Series 1 Convertible Preferred Stock had no expiration date.
F3TUA of Armando Anido and Nancy J. Anido Trust are controlled by Armando Anido, who has voting and dispositive power with respect to the shares held by the trusts.